MNK - Mallinckrodt plc

NYSE - NYSE Delayed Price. Currency in USD
3.4100
+0.0300 (+0.89%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close3.3800
Open3.4900
Bid3.3500 x 4000
Ask3.4100 x 1100
Day's Range3.3500 - 3.5300
52 Week Range1.4300 - 27.3300
Volume4,083,372
Avg. Volume9,880,868
Market Cap305.666M
Beta (3Y Monthly)2.53
PE Ratio (TTM)N/A
EPS (TTM)-42.5070
Earnings DateFeb 24, 2020 - Feb 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • PR Newswire

    Mallinckrodt Presents Data on a Novel Predictive Model to Identify Infants at Risk for Infantile Spasms (IS) at the 2019 Annual Meeting of the American Epilepsy Society (AES)

    Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced findings on the use of a novel predictive model designed to more quickly identify infants with infantile spasms (IS), a rare seizure disorder that typically occurs between three and seven months of age.1 The study results were reported in a poster presentation titled, "Clinical Pathways Leading to a Diagnosis of Infantile Spasms Using a Claims Database," (Poster 1.209) today during the 2019 Annual Meeting of the American Epilepsy Society (AES) in Baltimore.

  • Two St. Louis companies make list of 15 worst corporate deals
    American City Business Journals

    Two St. Louis companies make list of 15 worst corporate deals

    Two St. Louis companies were involved in a couple of the 15 worst cooperate biotech deals of the past 10 years, according to FierceBiotech, a biotechnology news publication.

  • Mallinckrodt (MNK) Up 28.5% Since Last Earnings Report: Can It Continue?
    Zacks

    Mallinckrodt (MNK) Up 28.5% Since Last Earnings Report: Can It Continue?

    Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • PR Newswire

    Mallinckrodt plc Announces Final Results of Exchange Transactions

    Mallinckrodt plc (NYSE: MNK) today announced (1) the final results of the previously announced offers by its wholly owned subsidiaries, Mallinckrodt International Finance S.A. and Mallinckrodt CB LLC (the "Issuers") to Eligible Holders (as defined below) to exchange (the "Exchange Offers") certain outstanding notes (collectively, the "Existing Notes") issued by the Issuers for new 10.000% Second Lien Senior Secured Notes due 2025 to be issued by the Issuers (collectively, the "New Notes") and solicitations of consents by the Issuers from Eligible Holders of each series of Existing Notes (other than the Existing 4.750% 2023 Notes) to Proposed Amendments (as defined below) to the indentures governing such Existing Notes (the "Consent Solicitations") and (2) the Existing Notes anticipated to be exchanged with the Issuers, separate from the Exchange Offers, pursuant to that certain exchange agreement, dated as of November 5, 2019 and subsequently amended on November 27, 2019, by and among Deerfield Partners, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Private Design Fund IV, L.P. (such holders, the "Exchanging Holders") and the Issuers (as amended, the "Exchange Agreement").

  • J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders
    Zacks

    J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders

    J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.

  • PR Newswire

    Mallinckrodt Moves Date and Time of Its Fireside Chat at Piper Jaffray Annual Healthcare Conference

    Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that the Company now will present at the Piper Jaffray Annual Healthcare Conference on Wednesday, Dec. 4, 2019 at 12:30 p.m. Eastern.

  • Possible criminal probe undermines recovery in opioid stocks since global legal settlement announced
    MarketWatch

    Possible criminal probe undermines recovery in opioid stocks since global legal settlement announced

    The stock prices of opioid drugmakers and distributors fell this week after news of a possible federal criminal probe, eroding many of the gains made in the weeks since a global settlement resolving opioid litigation was first announced.

  • Barrons.com

    Opioid Stocks Fall on News of Federal Criminal Investigation

    Shares of companies caught up in the opioid litigation have risen recently, but a Wall Street Journal report appears to have reminded investors that the trouble could continue.

  • Benzinga

    Benzinga Pro's Stocks To Watch For Wednesday, Nov. 27th, 2019: DE, ADSK, GES, MNK, AMZN

    Benzinga Pro's Stocks To Watch For Wednesday Deere (DE)  - The stock traded 4% lower in pre-market trading after  the company guided FY20 agricultural sales down 5%-10%. The company said trade tensions ...

  • Fed Reportedly Opens Criminal Investigation on Opioid Makers
    Zacks

    Fed Reportedly Opens Criminal Investigation on Opioid Makers

    Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.

  • Benzinga

    Pharma Companies Shares Tank As Feds Investigate Opioid Crisis

    Pharmaceutical companies are in trouble over their role in fueling the opioid crisis facing the U.S. What Happened Federal authorities have launched a criminal investigation against the companies — using ...

  • MarketWatch

    Shares of opioid makers and distributors drop on criminal probe

    Shares of the companies embroiled in opioid litigation fell in afternoon trading afterThe Wall Street Journal reported the federal government had opened a criminal investigation into some opioid makers and distributors, citing sources. Six companies have disclosed in regulatory filings that they have received grand-jury subpoenas from the U.S. attorney's office in the Eastern District of New York, according to the report. Teva Pharmaceutical Industries Ltd. is down 8%, Mallinckrodt 5%, Amneal Pharmaceuticals Inc. 10%, and Johnson & Johnson 1%. Shares of cited wholesale drug distributors also declined, AmerisourceBergen by 3% and McKesson by 5%. In addition, shares of companies facing opioid litigation but not cited in the Journal story also dropped, with Endo International down 9% and Cardinal Health 4%. In recent weeks, the stocks of these companies have rallied as investors took the view that the possibility of global settlement that would resolve all pending and future litigation was a positive.

  • Shares of generic drugmakers rise on hope that legal issues are nearing an end
    MarketWatch

    Shares of generic drugmakers rise on hope that legal issues are nearing an end

    Shares of generic drugmakers jumped Monday as speculation mounts about a series of legal settlements potentially nearing a resolution.

  • PR Newswire

    Data on Acthar® Gel (Repository Corticotropin Injection) Therapy in Symptomatic Sarcoidosis Published in Therapeutic Advances in Respiratory Disease

    Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced findings from a large retrospective study of Acthar® Gel (repository corticotropin injection) in the treatment of the respiratory disease symptomatic sarcoidosis that assessed patient characteristics, treatment patterns, concomitant medication use and physicians' assessments of treatment response. The study examined medical records from 302 patients with advanced symptomatic sarcoidosis, the majority of whom had comorbidities and had previously been treated with corticosteroids. The analysis showed that the use of Acthar Gel was associated with improved overall health status in 95 percent of patients as reported by physicians' assessments, with more than half of patients (54 percent) seeing improvements in two or more symptoms. In addition, there was an association observed between the use of Acthar Gel therapy and reduced overall use of other medications. Results of the study were recently published online in Therapeutic Advances in Respiratory Disease, an online, open-access peer-reviewed journal.

  • MarketWatch

    Shares of generic drugmakers jump in morning trading

    Shares of generic drugmakers are up in morning trading, with Mallinckrodt leading the pack as its stock rallied 15%. Teva Pharmaceutical Industries Ltd. is up 5%, Mylan up 4% and Endo International 4%. Bloomberg reported Monday morning that sources have said Teva and other drugmakers, including Sun Pharmaceutical Industries, are in talks with the Department of Justice to resolve allegations of price-fixing in the generic drug market. Separately, SVB Leerink analysts said this week that if plans for Endo, Mallinckrodt and Teva to enter into a "global opioid settlement framework" with state attorneys general go through, likely in the fourth quarter of 2019 or the first quarter of 2020, it would be a positive for those companies. "We could also see read-through for other opioid-levered names like Endo and Mallinckrodt," the analysts wrote in a Nov. 24 note.

  • Arnold Schneider Trims Positions in Chesapeake, Citigroup
    GuruFocus.com

    Arnold Schneider Trims Positions in Chesapeake, Citigroup

    Guru's larges sales of the 3rd quarter Continue reading...

  • Endo's (ENDP) BLA for Cellulite Treatment Accepted by FDA
    Zacks

    Endo's (ENDP) BLA for Cellulite Treatment Accepted by FDA

    The FDA accepts Endo's (ENDP) BLA for CCH for the treatment of cellulite in the buttocks.

  • Market Exclusive

    Market Morning: GM Sues Fiat, Pharma Fights for Pricing Privacy, More Opioid Lawsuits, Trade Deal Troubles

    GM Sues Fiat Chrysler Over Corrupt Union Dealings General Motors (NYSE:GM) is suing Fiat Chrysler (NYSE:FCAU) alleging racketeering regarding its negotiations with the United Auto Workers union from back in 2015. Fiat Chrysler executives have already pleaded guilty in an ongoing probe into the UAW, whose own executives accepted bribes from Chrysler people over the […]The post Market Morning: GM Sues Fiat, Pharma Fights for Pricing Privacy, More Opioid Lawsuits, Trade Deal Troubles appeared first on Market Exclusive.

  • Thomson Reuters StreetEvents

    Edited Transcript of MNK earnings conference call or presentation 5-Nov-19 1:30pm GMT

    Q3 2019 Mallinckrodt Plc Earnings Call

  • PR Newswire

    Mallinckrodt plc Announces Early Results of Exchange Transactions

    STAINES-UPON-THAMES, United Kingdom , Nov. 19, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:  MNK) today announced (1) the early results of the previously announced offers by its wholly owned subsidiaries, ...

  • PR Newswire

    Mallinckrodt to Present at Piper Jaffray Annual Healthcare Conference

    STAINES-UPON-THAMES, United Kingdom , Nov. 19, 2019 /PRNewswire/ --  Mallinckrodt plc  (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, Dec. 3, 2019 , at the Piper Jaffray Annual ...

  • Value Investor Bill Miller’s New Stock Picks
    Insider Monkey

    Value Investor Bill Miller’s New Stock Picks

    Miller Value Partners recently released its 2019 Q3 investor letter – you can download a copy here. We just published another article about Bill Miller's comments earlier today. The investment management firm did not have a good third quarter, experiencing a 1.81% decline, while the S&P 500 rose 1.70%. One of the top contributors for the fund over the […]

  • Benzinga

    The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan ...

  • PR Newswire

    Mallinckrodt Announces New Clinical Data Evaluating Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting

    -- New analysis from Phase 4 study in RA showed that statistically significant improvement from baseline in patient-reported outcomes for pain, fatigue, physical functioning and work-related impairment ...

  • PR Newswire

    Mallinckrodt Presents Positive Phase 3 Results from its CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019

    -- Study showed a statistically significant number of patients on terlipressin achieved the primary endpoint of Verified HRS Reversal vs placebo -- -- CONFIRM is the largest prospective study (n=300) conducted ...